Linked Life Data

11249601

Source:http://linkedlifedata.com/resource/pubmed/id/11249601

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2001-3-15
pubmed:abstractText
BP-294 (a prodrug of R-alpha-methylhistamine) is a histamine H3 agonist under development by Bioprojet and in phase II clinical trials as an antiasthmatic [219798]. In a study, R-alpha-methylhistamine was shown to inhibit the release of acetylcholine, in the presence of atropine (1 microM) and 0.5 Hz of electrical stimulation of the rat bilateral vagus nerve, in a dose-dependent manner. This inhibition was abolished by thioperamide [321838].
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1472-4472
pubmed:author
pubmed:issnType
Print
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
86-9
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
BP-294 Ste Civile Bioprojet.
pubmed:affiliation
Novartis Preclinical Research, Asthma Building 386/1035, Postfach, CH-4002 Basel, Switzerland. john_r.fozard@pharma.novartis.com
pubmed:publicationType
Journal Article, Review